S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in

Inogen Stock Forecast, Price & News

+0.65 (+1.24 %)
(As of 03/1/2021 12:00 AM ET)
Today's Range
Now: $53.14
50-Day Range
MA: $50.48
52-Week Range
Now: $53.14
Volume180,198 shs
Average Volume167,099 shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Inogen logo


Earnings Outlook For Inogen
February 25, 2021 |  benzinga.com
Inogen, Inc. to Host Earnings Call - Yahoo Finance
February 24, 2021 |  finance.yahoo.com
Recap: Inogen Q4 Earnings - Yahoo Finance
February 24, 2021 |  finance.yahoo.com
Inogen Announces Fourth Quarter 2020 Financial Results
February 24, 2021 |  finance.yahoo.com
Recap: Inogen Q4 Earnings
February 24, 2021 |  finance.yahoo.com
Inogen Inc (INGN) Q4 2020 Earnings Call Transcript
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:INGN
Year FoundedN/A



Sales & Book Value

Annual Sales$361.94 million
Cash Flow$1.95 per share
Book Value$15.67 per share


Net Income$20.95 million


Market Cap$1.18 billion
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.36 out of 5 stars

Medical Sector

621st out of 1,966 stocks

Surgical Appliances & Supplies Industry

13th out of 40 stocks

Analyst Opinion: 2.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.65 (+1.24 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Inogen (NASDAQ:INGN) Frequently Asked Questions

Is Inogen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View analyst ratings for Inogen
or view top-rated stocks.

What stocks does MarketBeat like better than Inogen?

Wall Street analysts have given Inogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Inogen?

Inogen saw a decline in short interest in February. As of February 12th, there was short interest totaling 921,600 shares, a decline of 19.2% from the January 28th total of 1,140,000 shares. Based on an average daily trading volume, of 163,100 shares, the days-to-cover ratio is currently 5.7 days. Approximately 5.0% of the company's shares are short sold.
View Inogen's Short Interest

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Inogen

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Wednesday, February, 24th. The medical technology company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.05. Inogen had a positive trailing twelve-month return on equity of 0.21% and a negative net margin of 0.66%.
View Inogen's earnings history

How has Inogen's stock been impacted by COVID-19 (Coronavirus)?

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INGN stock has increased by 30.9% and is now trading at $53.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for INGN?

4 equities research analysts have issued 12 month target prices for Inogen's shares. Their forecasts range from $54.00 to $75.00. On average, they expect Inogen's stock price to reach $63.00 in the next year. This suggests a possible upside of 18.6% from the stock's current price.
View analysts' price targets for Inogen
or view top-rated stocks among Wall Street analysts.

Who are Inogen's key executives?

Inogen's management team includes the following people:
  • Mr. Brenton Taylor, Co-Founder & Exec. VP of Engineering (Age 40, Pay $325.88k)
  • Ms. Alison Perry Bauerlein, Co-Founder, Exec. VP of Fin., CFO, Corp. Sec. & Corp. Treasurer (Age 40, Pay $371.06k)
  • Mr. Byron Myers, Co-Founder & Exec. VP of Marketing (Age 42, Pay $356.95k)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 55, Pay $372.87k)
  • Mr. Scott Wilkinson, Exec. Officer (Age 56, Pay $520.62k)
  • Mr. Nabil Shabshab, Pres, CEO & Director (Age 56)
  • Mr. Matthew James Bacso C.F.A., CFA, Investor Relations & Corp. Devel. Mang.
  • Mr. Arron Retterer, Exec. VP of Sales
  • Mr. Matthew Pigeon, Investor Relations Officer

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen CEO Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among Inogen's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (17.96%), BlackRock Inc. (14.03%), SummerHaven Investment Management LLC (2.34%), Dimensional Fund Advisors LP (2.17%), Bamco Inc. NY (2.11%) and Renaissance Technologies LLC (1.34%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Heath Lukatch and Loren L Mcfarland.
View institutional ownership trends for Inogen

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Engineers Gate Manager LP, Matarin Capital Management LLC, Voloridge Investment Management LLC, Bank of New York Mellon Corp, and Hunter Associates Investment Management LLC. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, and Brenton Taylor.
View insider buying and selling activity for Inogen
or view top insider-selling stocks.

Which major investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including SummerHaven Investment Management LLC, Bamco Inc. NY, JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Brown Capital Management LLC, Riverbridge Partners LLC, and Gyon Technologies Capital Management LP. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen
or or view top insider-buying stocks.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $53.14.

How much money does Inogen make?

Inogen has a market capitalization of $1.18 billion and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does Inogen have?

Inogen employs 1,020 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

Where are Inogen's headquarters?

Inogen is headquartered at 326 BOLLAY DRIVE, GOLETA CA, 93117.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]

This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.